Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Aisner

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Cancer Chemotherapy and Pharmacology|November 30, 2013
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancerTaofeek K Owonikoko, Joseph Aisner, Xin Victoria Wang, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2020
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2020
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
Investigational New Drugs|August 8, 2019
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumorsMark N Stein, Susan Goodin, Murugeson Gounder, et al.
Anti-Cancer Drugs|May 6, 2008
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemiaBiren Saraiya, Murugesan Gounder, Jayeeta Dutta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetateRoger K Strair, Dale Schaar, Lauri Goodell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemiaRoger K Strair, Mecide Gharibo, Dale Schaar, et al.
Annals of Translational Medicine|April 26, 2019
Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancerBenedict Osorio, Nikhil Yegya-Raman, Sinae Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancerHelen J Ross, George R Blumenschein, Joseph Aisner, et al.
JAMA Oncology|February 21, 2020
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialSalma K Jabbour, Abigail T Berman, Roy H Decker, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Cancer Chemotherapy and Pharmacology|November 30, 2013
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancerTaofeek K Owonikoko, Joseph Aisner, Xin Victoria Wang, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2020
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2020
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
Investigational New Drugs|August 8, 2019
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumorsMark N Stein, Susan Goodin, Murugeson Gounder, et al.
Anti-Cancer Drugs|May 6, 2008
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemiaBiren Saraiya, Murugesan Gounder, Jayeeta Dutta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetateRoger K Strair, Dale Schaar, Lauri Goodell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemiaRoger K Strair, Mecide Gharibo, Dale Schaar, et al.
Annals of Translational Medicine|April 26, 2019
Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancerBenedict Osorio, Nikhil Yegya-Raman, Sinae Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancerHelen J Ross, George R Blumenschein, Joseph Aisner, et al.
JAMA Oncology|February 21, 2020
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialSalma K Jabbour, Abigail T Berman, Roy H Decker, et al.
Pageof 7